Literature DB >> 26380005

Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis.

Yimin Zhang1, Jun Yang2, Hongjuan Li3, Yihua Wu4, Honghe Zhang4, Wenhu Chen1.   

Abstract

BACKGROUND: Pancreatic cancer has the worst prognosis and early detection is crucial for improving patient prognosis. Therefore, we performed a meta-analysis to evaluate and compare the sensitivity and specificity of single test of CA19-9, CA242, and CEA, as well as combination test in pancreatic cancer detection.
METHODS: We searched PubMed, Embase, Medline, and Wanfang databases for studies that evaluated the diagnostic validity of CA19-9, CA242, and CEA between January 1990 and September 2014. Data were analyzed by Meta-Disc and STATA software.
RESULTS: A total of 21 studies including 3497 participants, which fulfilled the inclusion criteria were considered for analysis. The pooled sensitivities for CA19-9, CA242, and CEA were 75.4 (95% CI: 73.4-77.4), 67.8 (95% CI: 65.5-70), and 39.5 (95% CI: 37.3-41.7), respectively. The pooled specificities of CA19-9, CA242, and CEA were 77.6 (95% CI: 75.4-79.7), 83 (95% CI: 81-85), and 81.3 (95% CI: 79.3-83.2), respectively. Parallel combination of CA19-9+CA242 has a higher sensitivity (89, 95% CI: 80-95) without impairing the specificity (75, 95% CI: 67-82).
CONCLUSIONS: Our meta-analysis showed that CA242 and CA19-9 have better performance in the diagnosis of pancreatic cancer than CEA. Furthermore, parallel combination test of CA19-9+CA242 could be of better diagnostic value than individual CA242 or CA19-9 test.

Entities:  

Keywords:  CA19-9; CA242; CEA; meta-analysis; pancreatic cancer

Year:  2015        PMID: 26380005      PMCID: PMC4565388     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  10 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed.

Authors:  Jonathan J Deeks; Petra Macaskill; Les Irwig
Journal:  J Clin Epidemiol       Date:  2005-09       Impact factor: 6.437

3.  [Pancreatic cancer in 2014: screening and epidemiology].

Authors:  Laurent Bochatay; Marc Girardin; Philippe Bichard; Jean-Louis Frossard
Journal:  Rev Med Suisse       Date:  2014-09-03

Review 4.  Epidemiology of pancreatic cancer: an update.

Authors:  Patrick Maisonneuve; Albert B Lowenfels
Journal:  Dig Dis       Date:  2010-11-18       Impact factor: 2.404

5.  Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society.

Authors:  Shinichi Egawa; Hiroki Toma; Hiroaki Ohigashi; Takuji Okusaka; Akimasa Nakao; Takashi Hatori; Hiroyuki Maguchi; Akio Yanagisawa; Masao Tanaka
Journal:  Pancreas       Date:  2012-10       Impact factor: 3.327

6.  The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.

Authors:  X G Ni; X F Bai; Y L Mao; Y F Shao; J X Wu; Y Shan; C F Wang; J Wang; Y T Tian; Q Liu; D K Xu; P Zhao
Journal:  Eur J Surg Oncol       Date:  2005-03       Impact factor: 4.424

7.  CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.

Authors:  Ji-Cong Gui; Wei-Li Yan; Xing-Dang Liu
Journal:  Clin Exp Med       Date:  2013-03-03       Impact factor: 3.984

Review 8.  Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.

Authors:  M J Duffy; C Sturgeon; R Lamerz; C Haglund; V L Holubec; R Klapdor; A Nicolini; O Topolcan; V Heinemann
Journal:  Ann Oncol       Date:  2009-08-18       Impact factor: 32.976

Review 9.  Advances in pancreatic cancer research: moving towards early detection.

Authors:  Xiang-Yi He; Yao-Zong Yuan
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

10.  Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.

Authors:  Quan Liao; Yu-Pei Zhao; Ying-Chi Yang; Li-Jun Li; Xiao Long; Shao-Mei Han
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2007-12
  10 in total
  61 in total

Review 1.  Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have.

Authors:  Marta Herreros-Villanueva; Luis Bujanda
Journal:  Ann Transl Med       Date:  2016-04

2.  Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy.

Authors:  Katherine S Yang; Hyungsoon Im; Seonki Hong; Ilaria Pergolini; Andres Fernandez Del Castillo; Rui Wang; Susan Clardy; Chen-Han Huang; Craig Pille; Soldano Ferrone; Robert Yang; Cesar M Castro; Hakho Lee; Carlos Fernandez Del Castillo; Ralph Weissleder
Journal:  Sci Transl Med       Date:  2017-05-24       Impact factor: 17.956

3.  Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer.

Authors:  Lianyuan Tao; Juntuo Zhou; Chunhui Yuan; Lingfu Zhang; Deyu Li; Dandan Si; Dianrong Xiu; Lijun Zhong
Journal:  Metabolomics       Date:  2019-05-30       Impact factor: 4.290

4.  Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.

Authors:  Petr Karasek; Natalia Gablo; Jan Hlavsa; Igor Kiss; Petra Vychytilova-Faltejskova; Marketa Hermanova; Zdenek Kala; Ondrej Slaby; Vladimir Prochazka
Journal:  Cancer Genomics Proteomics       Date:  2018 Jul-Aug       Impact factor: 4.069

5.  Genome-wide screening identifies oncofetal lncRNA Ptn-dt promoting the proliferation of hepatocellular carcinoma cells by regulating the Ptn receptor.

Authors:  Jin-Feng Huang; Hong-Yue Jiang; Hui Cai; Yan Liu; Yi-Qing Zhu; Sha-Sha Lin; Ting-Ting Hu; Tian-Tian Wang; Wen-Jun Yang; Bang Xiao; Shu-Han Sun; Li-Ye Ma; Hui-Rong Yin; Fang Wang
Journal:  Oncogene       Date:  2019-01-14       Impact factor: 9.867

6.  Efficiency of Gastrointestinal Cancer Detection by Nematode-NOSE (N-NOSE).

Authors:  Hirotake Kusumoto; Kotaro Tashiro; Syunji Shimaoka; Koichiro Tsukasa; Yukiko Baba; Saori Furukawa; Junichiro Furukawa; Toru Niihara; Takaaki Hirotsu; Takayuki Uozumi
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

Review 7.  Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes.

Authors:  Xu Zhang; Si Shi; Bo Zhang; Quanxing Ni; Xianjun Yu; Jin Xu
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

Review 8.  Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy.

Authors:  Krishna Patel; Sohail Siraj; Chloe Smith; Maya Nair; Jamboor K Vishwanatha; Riyaz Basha
Journal:  Crit Rev Oncog       Date:  2019

9.  Prognostic value of glypican-1 for patients with advanced pancreatic cancer following regional intra-arterial chemotherapy.

Authors:  Jing-Yu Qian; Yu-Lin Tan; Yang Zhang; Yong-Fei Yang; Xiao-Qiang Li
Journal:  Oncol Lett       Date:  2018-05-11       Impact factor: 2.967

10.  Extracellular Vesicle Analysis Allows for Identification of Invasive IPMN.

Authors:  Katherine S Yang; Debora Ciprani; Aileen O'Shea; Andrew S Liss; Robert Yang; Sarah Fletcher-Mercaldo; Mari Mino-Kenudson; Carlos Fernández-Del Castillo; Ralph Weissleder
Journal:  Gastroenterology       Date:  2020-12-07       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.